GV returned for a series C round that helped the precision cancer medicine developer increase its overall funding to over $180m.

FogPharma, a US-based cancer precision medicine developer received $107m on Wednesday in a series C round featuring GV, a corporate venturing subsidiary of internet and technology group Alphabet. The round was led by life sciences investment firm VenBio Partners and included 6 Dimensions Capital, an investment firm co-founded by pharmaceutical firm WuXi AppTec. Cormorant Asset…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.